May 13, 2026
Tesamorelin Research: GHRH Analog and Metabolic Models
Explore preclinical and clinical research on Tesamorelin, a 44-amino acid GHRH analog studied for visceral adiposity, GH pulse dynamics, and metabolic markers.
RESEARCH NOTES
May 13, 2026
Explore preclinical and clinical research on Tesamorelin, a 44-amino acid GHRH analog studied for visceral adiposity, GH pulse dynamics, and metabolic markers.
May 13, 2026
Preclinical research on Pinealon (EDR tripeptide): epigenetic mechanisms, neuroprotective effects in animal models, and cognitive aging from the Khavinson lab.
May 13, 2026
NAD+ research in preclinical models reveals sirtuin activation, PARP competition, and mitochondrial effects. Review the evidence on NAD+ and longevity.
May 13, 2026
Orforglipron GLP-1 research: non-peptide small molecule, oral bioavailability, ATTAIN phase 3 data, and mechanistic comparison to semaglutide and tirzepatide.
May 13, 2026
Melanotan-2 research covers MC1R and MC4R agonism, skin pigmentation in animal models, and neuroprotective melanocortin signalling in preclinical studies.
May 6, 2026
Explore 2026 preclinical research on oral peptides metabolic effects — GLP-1, BPC-157, MOTS-c, and NAD+ data from rodent animal model studies reviewed here.
May 6, 2026
Explore preclinical animal model data on oral GLP-1 appetite regulation, covering food intake, satiety hormones, and hypothalamic GLP-1R activation research.
May 6, 2026
Preclinical studies on BPC-157 arginate vs acetate salt forms examine degradation rates, pH stability, and oral delivery behaviour in research models.
May 6, 2026
BPC-157 and GLP-1 longevity research: overlapping mechanisms in metabolic health, cellular repair, mitochondrial function and preclinical anti-aging data.
May 6, 2026
GLP-1 research compounds vs oral semaglutide: preclinical mechanism comparison, bioavailability data, and what laboratory models show about each compound class.